Guide Angels

What Is Microdosing?

Microdosing refers to the practice of consuming sub-perceptual quantities of psychedelic substances, most commonly psilocybin (from psilocybin mushrooms) or LSD (lysergic acid diethylamide), at doses too small to produce overt psychedelic effects while potentially producing subtle improvements in mood, cognition, creativity, and spiritual sensitivity. A typical microdose is approximately one-tenth to one-twentieth of a standard psychoactive dose: roughly 0.1-0.3 grams of dried psilocybin mushrooms (compared to a full psychedelic dose of 2-5 grams) or 5-15 micrograms of LSD (compared to 75-150 micrograms for a full experience).

The concept is not new. Indigenous plant medicine traditions have long used varying doses of psychoactive plants in different ceremonial contexts, from full visionary doses for specific healing or divination purposes to smaller doses for more subtle ceremonial, social, or medicinal use. What is new is the contemporary secular practice of microdosing for productivity, wellbeing, creativity, and spiritual development outside of traditional ceremonial frameworks, and the emerging scientific research evaluating these claims.

Interest in microdosing exploded following coverage in mainstream media beginning around 2015, with stories about Silicon Valley professionals microdosing for productivity sparking global curiosity. This initial framing as a productivity hack partly obscured the deeper spiritual and therapeutic dimensions that serious practitioners and researchers have focused on. The most meaningful research, and the most meaningful reported benefits, center on psychological healing, spiritual development, and the reduction of mental suffering rather than performance optimization.

James Fadiman and the Psychedelic Explorer's Guide

James Fadiman, PhD, a psychologist who has studied psychedelics since the 1960s, conducted some of the earliest controlled psilocybin research at Stanford University in 1966 before the US government halted such research. He later wrote the definitive guide to responsible psychedelic use, The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys (2011), which remains one of the most comprehensive and responsible treatments of the subject for both practitioners and researchers.

Fadiman's contribution to microdosing specifically began with his collection of self-reported data from hundreds of people who had already begun microdosing on their own initiative in the early 2010s. His informal protocol, which became known as the Fadiman Protocol, was developed from this observational data: one microdose day, two days off, repeat. This schedule allows observation of both dose-day and non-dose-day effects, helps prevent tolerance development (psilocybin and LSD both develop tolerance rapidly with consecutive dosing), and structures the practice for systematic self-observation.

Fadiman's observational data, summarized in various presentations and later publications, suggested that approximately 80% of his respondents reported positive experiences with microdosing, with the most common reported benefits being improved mood, increased focus and creative thinking, reduced anxiety, enhanced empathy and compassion, and improved wellbeing generally. Adverse effects were reported by approximately 20% and included increased anxiety on dose days, emotional sensitivity, headache, and in some cases, worsening of pre-existing mental health conditions.

A 2019 pre-registered observational study published in Psychopharmacology by Vince Polito and Richard Stevenson followed 98 microdosers prospectively over six weeks. Results were mixed: they found improvements in absorption (a measure of openness and presence), neuroticism reduction, and improved contemplative focus. However, they also found some negative effects and called for more rigorous controlled trials. Their data highlighted the importance of placebo-controlled study, as expectation effects in self-selected microdosing samples are substantial.

Johns Hopkins Research on Psilocybin

The Johns Hopkins Center for Psychedelic and Consciousness Research, led by psychiatrist Matthew Johnson and pharmacologist Roland Griffiths, has produced some of the most significant clinical research on psilocybin in the current research renaissance. Their work has focused primarily on full-dose psilocybin therapy rather than microdosing, but the mechanisms revealed are directly relevant to understanding why microdosing practitioners report the effects they do.

Their 2006 landmark study in Psychopharmacology demonstrated that a single high-dose psilocybin session produced mystical experiences in healthy volunteers that were rated as among the most significant experiences of their lives two months later. The study was the first peer-reviewed demonstration of psilocybin's mystical effects under controlled conditions since the research moratorium of the early 1970s, and it effectively launched the current clinical research renaissance.

Subsequent Johns Hopkins studies have demonstrated psilocybin's effectiveness for: major depressive disorder (a 2020 study in JAMA Psychiatry found significant antidepressant effects after two sessions lasting 4 weeks), treatment-resistant depression, anxiety and depression in cancer patients (where two sessions produced significant reductions lasting months), smoking cessation (80% abstinence rate at 6 months, dramatically exceeding existing treatments), and alcohol use disorder.

A 2022 survey study from Johns Hopkins examining the specific spiritual applications of psilocybin found that 75% of respondents who reported spiritual or religious motivations for psilocybin use rated their experiences as among the most spiritually significant of their lives. The study documented lasting increases in life satisfaction, wellbeing, and sense of meaning following these experiences.

The Neuroscience of Psilocybin

Neuroscientist Robin Carhart-Harris, first at Imperial College London and now at University of California San Francisco, has conducted landmark neuroimaging research revealing how psilocybin affects the brain in ways directly relevant to both therapeutic and spiritual applications.

Psilocybin is metabolized in the body to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors, the receptor type most associated with psychedelic effects. In the brain, this produces several measurable effects visible in fMRI neuroimaging:

Default Mode Network (DMN) disruption: The DMN, a network of brain regions active during self-referential thinking, rumination, and mind-wandering, shows reduced activity and reduced internal coherence under psilocybin. The DMN is associated with the narrativizing, self-evaluating "ego" mind that many spiritual traditions seek to quiet. Its temporary disruption may explain the ego-dissolution and reduction in self-referential suffering that characterizes therapeutic and spiritual psilocybin experiences.

Increased neural entropy and connectivity: Psilocybin increases entropy (randomness and complexity) in brain activity and enhances connectivity between brain regions that do not normally communicate directly. This "hyperconnected" state may underlie the unusual thought associations, creative insights, and feelings of unity and interconnection characteristic of psychedelic experience.

BDNF and neuroplasticity: Psilocybin increases BDNF (brain-derived neurotrophic factor) levels, promoting the neural growth and rewiring that makes new learning and habit change possible. This neuroplasticity window following psilocybin use is thought to explain why therapeutic sessions are followed by weeks during which behavioral change and new perspective adoption are easier than baseline.

Reported Spiritual Benefits

Across Fadiman's survey data, Johns Hopkins studies, and extensive first-person practitioner reports, consistent patterns of spiritual benefit emerge. These are reported effects, not clinical claims, and individual variation is substantial:

Enhanced Presence and Mindfulness: Among the most consistently reported microdosing benefits is a heightened quality of present-moment awareness on dose days. The increased sensory aliveness, reduced mind-wandering, and easier access to beginner's mind that practitioners describe closely resemble the qualities cultivated through long-term meditation practice.

Reduced Ego-Identification: Even at sub-perceptual doses, some practitioners report subtle but meaningful reduction in the grip of self-referential narratives, the inner critic, and the defended ego structure that prevents authentic contact with others and with deeper layers of self. This effect is presumably a minor expression of the more dramatic ego-dissolution that full doses produce.

Increased Compassion and Empathy: Reports of increased emotional accessibility, genuine interest in others, and warm-hearted openness on microdose days are consistent across practitioner communities. Research on full-dose psilocybin consistently shows it increases prosocial behavior and empathy measures.

Nature Connection and Awe: Many practitioners describe an increased appreciation for natural beauty, a heightened sense of awe in ordinary environments, and a felt sense of connection to the natural world that they describe as profoundly spiritual in character.

Creative and Intuitive Opening: Enhanced creative flow, more fluid associative thinking, and increased access to intuitive knowing are frequently reported. These effects likely reflect the increased neural connectivity and reduced default mode network rigidity documented in neuroimaging research.

Microdosing Protocols

Risks, Contraindications, and Honest Assessment

An honest guide to microdosing for spiritual growth must give equal weight to risks as to benefits. The enthusiastic coverage in popular media has significantly underweighted risks, and responsible harm reduction requires clear-eyed assessment:

Psychological Risk for Vulnerable Populations: Psilocybin is contraindicated for people with personal or family history of schizophrenia, psychosis, bipolar disorder I (the type with manic episodes), or borderline personality disorder with psychotic features. Even sub-perceptual doses may provoke episodes in these populations. This contraindication is not theoretical; clinical trials uniformly exclude these populations for this reason.

Anxiety Amplification: Psilocybin amplifies whatever psychological state it finds. Microdosers with significant underlying anxiety sometimes report that microdosing increases rather than decreases anxiety, particularly on dose days. This is not universal but is reported by a meaningful minority.

Tolerance and Habituation: Serotonergic psychedelics develop rapid tolerance. The Fadiman Protocol's built-in rest days address this, but some practitioners report diminishing effects over weeks even with rest days. Taking more to compensate is the path toward problematic use patterns.

Uncertainty about Long-Term Safety: Most clinical trials are 4-12 weeks in duration. We do not have long-term safety data on microdosing specifically. Animal studies show some evidence of cardiac valve changes with prolonged serotonergic agonist use at higher doses; whether these risks apply at microdosing doses and duration is unknown.

Legal Risk: In most jurisdictions, psilocybin mushrooms remain controlled substances. Possession, cultivation, and use carry criminal penalties that vary from minor to severe depending on location, quantity, and context. This is a real practical risk that practitioners must assess honestly for their specific situation.

Legal Status and Considerations

The legal landscape for psilocybin is changing rapidly but unevenly. In the United States: psilocybin remains Schedule I federally. Oregon passed Measure 109 in 2020, creating a regulated therapeutic psilocybin program that opened in 2023. Colorado legalized regulated therapeutic use through Proposition 122 in 2022. Cities including Denver, Oakland, Santa Cruz, and Washington D.C. have decriminalized possession. Canada has authorized psilocybin use for palliative care patients and some clinical trial participants.

In the United Kingdom, Netherlands, Portugal, and many other countries, psilocybin mushrooms remain controlled. The Netherlands has a gray market around "magic truffles" (the sclerotia of psilocybin mushrooms, which are technically distinct from mushrooms under Dutch law) that has operated for decades.

The responsible approach for spiritually motivated practitioners is to be honest about the legal reality in their jurisdiction, consult legal resources rather than online communities for accurate information, and make informed decisions about their own risk tolerance rather than following social media enthusiasm into legal jeopardy.

Legal Non-Psychedelic Alternatives

For practitioners interested in the neurological and spiritual benefits associated with microdosing but unwilling or unable to use controlled substances, several legal alternatives have supporting evidence:

Lion's Mane Mushroom (Hericium erinaceus): A culinary and medicinal mushroom with documented effects on NGF (nerve growth factor) and BDNF production. Studies by Mori and colleagues (2009) published in Phytotherapy Research found lion's mane improved cognitive function in adults with mild cognitive impairment. It promotes neural growth without psychoactive effects and can be taken continuously without tolerance concerns.

The Stamets Stack (Legal Version): Mycologist Paul Stamets proposes combining lion's mane mushroom with niacin (flush niacin) for neurological benefit, without the psilocybin component. The niacin flush is theorized to help drive lion's mane compounds into peripheral neurological tissue. This is a practitioner hypothesis rather than clinical protocol, but the components are legal, safe, and reasonably evidenced individually.

Ketamine Therapy: Ketamine is a legal (with prescription) dissociative anesthetic that at sub-anesthetic doses produces rapid antidepressant effects through NMDA receptor antagonism. Ketamine-assisted therapy is available in many jurisdictions and has strong clinical evidence for treatment-resistant depression. While not a psychedelic in the classic serotonergic sense, its effects on neuroplasticity and consciousness share certain characteristics.

Psychedelics and Spiritual Tradition

The relationship between psychedelic substances and spiritual development is both ancient and contested within spiritual traditions themselves. The Eleusinian Mysteries of ancient Greece, one of the most significant religious institutions of the classical world practiced for nearly 2,000 years, may have involved a psychoactive kykeon drink containing ergot alkaloids related to LSD, as argued by classicist Carl Ruck and colleagues in The Road to Eleusis (1978). If so, some of the greatest spiritual and philosophical development of Western civilization was catalyzed by psychedelic experience.

Indigenous Mesoamerican traditions have used psilocybin mushrooms (known to the Mazatec as "little saints" and to the Nahuatl-speaking Aztec as teonanacatl, "flesh of the gods") in healing ceremonies for at least 3,000 years. The Peyote traditions of the Native American Church have used mescaline-containing peyote cactus in ceremonies since pre-Columbian times. These traditions provide living examples of psychedelics being used for genuine spiritual development within carefully held ceremonial containers.

Contemporary spiritual traditions take varying positions. Most established Buddhist teachers caution against psychedelics as a substitute for meditation practice, arguing that genuine spiritual development requires cultivating the capacity to access expanded states through practice rather than chemistry. Some teachers, including Adyashanti and others, distinguish between using psychedelics for genuine spiritual inquiry versus escapism or recreation. A minority of teachers embrace psychedelics as legitimate tools within a broader practice context.

Integration: The Essential Missing Piece

In both full-dose therapeutic and microdosing contexts, integration is described by researchers and practitioners alike as the most important and most commonly neglected component of beneficial psychedelic use. Extraordinary experiences, whether mystical, emotional, or creative, do not automatically translate into lasting transformation. The translation work is integration.

Integration for microdosing is ongoing rather than event-based: keeping a detailed journal on both dose and non-dose days, noting mood, energy, creativity, emotional accessibility, interpersonal quality, and spiritual sensitivity. Reviewing this journal weekly to identify patterns and inform practice decisions. Working with a therapist or integration coach during a microdosing period to help process what the practice surfaces. Aligning microdosing periods with active engagement in meditation, creative work, or therapeutic processing rather than treating it as a standalone intervention.

The neuroplasticity window that psilocybin opens, documented in neuroscience research as an increased BDNF and synaptic plasticity period following exposure, is most productively used by deliberately engaging new practices, perspectives, and relational patterns during this window rather than returning immediately to habitual patterns. Integration is what turns a window of neuroplasticity into actual neurological change.

Practical Considerations for the Spiritually Motivated

For spiritually motivated individuals considering microdosing, a thoughtful framework includes several preliminary steps before beginning any protocol:

First, honestly assess your psychological stability and history. If you have any personal or family history of psychotic episodes, schizophrenia, bipolar disorder I, or borderline personality disorder with psychotic features, microdosing with psilocybin is not appropriate for you. Second, assess your legal situation honestly. Third, if you have existing mental health conditions or take medications (especially antidepressants, as SSRIs blunt psilocybin effects and MAOIs create dangerous interactions), consult a physician who is knowledgeable about psychedelics.

Fourth, before starting any microdosing protocol, establish a strong foundation of other spiritual practices: daily meditation, regular somatic work, healthy sleep and nutrition, supportive social connections, and meaningful creative or service work in your life. Microdosing works best as an enhancement of an already-developing spiritual practice, not as a replacement for it or a shortcut around the work that genuine development requires.